Lipe & Dalton Makes New $482,000 Investment in Boston Scientific Corporation $BSX

Lipe & Dalton purchased a new stake in Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 11,300 shares of the medical equipment provider’s stock, valued at approximately $482,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. CYBER HORNET ETFs LLC raised its position in shares of Boston Scientific by 3.4% during the 3rd quarter. CYBER HORNET ETFs LLC now owns 4,004 shares of the medical equipment provider’s stock worth $391,000 after purchasing an additional 132 shares during the period. Gerber Kawasaki Wealth & Investment Management increased its position in Boston Scientific by 4.7% in the fourth quarter. Gerber Kawasaki Wealth & Investment Management now owns 3,082 shares of the medical equipment provider’s stock worth $294,000 after buying an additional 139 shares during the period. Northwestern Mutual Investment Management Company LLC lifted its stake in Boston Scientific by 0.3% in the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 47,366 shares of the medical equipment provider’s stock valued at $4,516,000 after buying an additional 140 shares during the last quarter. Kingsview Wealth Management LLC boosted its holdings in shares of Boston Scientific by 2.4% during the fourth quarter. Kingsview Wealth Management LLC now owns 6,066 shares of the medical equipment provider’s stock valued at $578,000 after acquiring an additional 142 shares during the period. Finally, RiverFront Investment Group LLC grew its position in shares of Boston Scientific by 0.7% during the fourth quarter. RiverFront Investment Group LLC now owns 21,308 shares of the medical equipment provider’s stock worth $2,032,000 after acquiring an additional 150 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific said manufacturing and shipping operations are recovering, which could limit the disruption’s longer-term impact. The company also expects seven product launches and cost savings to support a recovery by 2028. Boston Scientific’s 2026 Growth Outlook Weakens: Is Recovery Ahead?
• Neutral Sentiment: The company has not quantified the cyberattack’s full financial impact or provided a replacement forecast, leaving investors uncertain about the duration of operational disruptions and the pace of recovery. Boston Scientific says cyberattack likely to hurt 2026 sales, profit
• Negative Sentiment: Boston Scientific now expects it will not meet its previously issued 2026 sales and earnings guidance, including its third-quarter and full-year targets. The warning represents a material downgrade from its earlier outlook and is the main catalyst for the stock’s decline. Boston Scientific Says It Won’t Meet 2026 Guidance After Cyberattack
• Negative Sentiment: Separately, analysts cited pressure on the WATCHMAN and electrophysiology businesses, weakening the company’s near-term growth outlook even before the cyberattack’s effects are fully known. Boston Scientific’s 2026 Growth Outlook Weakens: Is Recovery Ahead?

Analysts Set New Price Targets

Several research firms have commented on BSX. Robert W. Baird set a $56.00 target price on shares of Boston Scientific in a research report on Thursday, July 30th. Wolfe Research lowered Boston Scientific from an “outperform” rating to a “peer perform” rating in a research report on Friday, May 29th. Bank of America cut their price objective on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. BTIG Research decreased their target price on shares of Boston Scientific from $65.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, July 29th. Finally, Zacks Research cut shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a research note on Friday, June 5th. Twenty-four analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $71.62.

Boston Scientific Price Performance

NYSE:BSX traded down $2.80 during mid-day trading on Tuesday, reaching $45.00. 29,020,296 shares of the stock were exchanged, compared to its average volume of 18,520,377. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $65.22 billion, a PE ratio of 18.22, a PEG ratio of 1.10 and a beta of 0.57. The business has a fifty day moving average price of $47.04 and a 200 day moving average price of $55.18.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The business had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Research analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific declared that its board has authorized a stock repurchase plan on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s management believes its shares are undervalued.

Insider Activity at Boston Scientific

In related news, Director Edward Ludwig purchased 5,000 shares of the company’s stock in a transaction that occurred on Friday, July 31st. The shares were purchased at an average price of $45.48 per share, with a total value of $227,400.00. Following the purchase, the director owned 30,359 shares of the company’s stock, valued at $1,380,727.32. This trade represents a 19.72% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Michael Mahoney acquired 186,240 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were bought at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the acquisition, the chief executive officer owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 194,522 shares of company stock worth $9,385,210 in the last quarter. 0.34% of the stock is owned by company insiders.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.